Mutation Analysis of IDH1/2 Genes in Unselected De novo Acute Myeloid Leukaemia Patients in India - Identification of A Novel IDH2 Mutation

Sureshkumar Raveendran¹, Santhi Sarojam¹, Sangeetha Vijay¹, Aswathy Chandran Geetha¹, Jayadevan Sreedharan², Geetha Narayanan³, Hariharan Sreedharan¹*¹

Abstract

IDH1/2 mutations which result in alternation in DNA methylation pattern are one of the most common methylation associated mutations in Acute myeloid leukaemia. IDH1/2 mutations frequently associated with higher platelet level, normal cytogenetics and NPM1 mutations. Here we analyzed IDH1/2 mutations in 200 newly diagnosed unselected Indian adult AML patients and investigated their correlation with clinical, cytogenetic parameters along with cooperating NPM1 mutation. We detected 5.5% and 4% mutations in IDH1/2 genes, respectively. Except IDH2 c.515_516GG>AA mutation, all the other identified mutations were reported mutations. Similar to reported c.515G>A mutation, the novel c.515_516GG>AA mutation replaces 172nd arginine to lysine in the active site of the enzyme. Even though there was a preponderance of IDH1/2 mutations in NK-AML, cytogenetically abnormal patients also harboured IDH1/2 mutations. IDH1 mutations showed significant higher platelet count and NPM1 mutations. IDH2 mutated patients displayed infrequent NPM1 mutations and lower WBC count. All the NPM1 mutations in the IDH1/2 mutated cases showed type A mutation. The present data suggest that IDH1/2 mutations are associated with normal cytogenetics and type A NPM1 mutations in adult Indian AML patients.

Keywords: Acute myeloid leukaemia - IDH1 - IDH2 - Type A NPM1 mutation

Asian Pac J Cancer Prev, 16 (9), 4095-4101

Introduction

Acute myeloid leukemia (AML) is a heterogeneous disease with poor outcome as a result of clonal transformation of hematopoietic precursors through gaining multiple gene mutations and chromosomal rearrangements. The cytogenetic analysis of AML cells is routinely used by the clinicians owing to its pivotal role in both diagnosis and predicting outcome in AML patients (Mardis et al., 2009). Recurrent chromosomal structural variations in AML are well established as diagnostic and prognostic markers, suggesting that acquired genetic abnormalities (i.e., somatic mutations) have an essential role in pathogenesis. However, approximately 50% of AML samples have a normal karyotype (NK-AML), and many of these genomes lack structural variations, even when analyzed with high density comparative genomic hybridization or SNP arrays (Ley et al., 2013). A fraction of these NK-AML patients are found to have mutations of genes that normally function in cell proliferation, differentiation and survival (e.g. NPM1, CEBPA, FLT3, RAS, WT1 etc.) (Chotirat et al., 2012). As a result of the advancement in whole genome sequencing techniques, a number of gene mutations that are related to epigenetic control of the genome have been found in AML patients (Conway et al., 2014). In 2009, using massively parallel DNA sequencing, Mardis et al. found that isocitrate dehydrogenase (IDH) which involved in cellular metabolism mutated in significant proportion of NK-AML patients (Mardis et al., 2009).

Among the three IDH isoforms (IDH1, IDH2 and IDH3), IDH1 and IDH2 have 70% structural resemblance in humans (Xu et al., 2004). IDH1 gene located on 2q33.3 and it produces cytoplasmic and peroxisomal protein. IDH2 gene located on 15q26.1 and unlike IDH1 it produces mitochondrial residing protein. IDH1 and IDH2 encoding enzymes interconverts isocitrate and α-ketoglutarate (αKG) by utilizing nicotinamide adenine dinucleotide (NAD) or NAD phosphate (NADP) as a cofactor (Dang et al., 2010). IDH1 gene located on 15q26.1 and unlike IDH1 it produces mitochondrial residing protein. IDH1 and IDH2 encoding enzymes interconverts isocitrate and α-ketoglutarate (αKG) by utilizing nicotinamide adenine dinucleotide (NAD) or NAD phosphate (NADP) as a cofactor (Dang et al., 2010). IDH1 mutations were first reported in a genome-wide mutation analysis of 22 glioblastoma multiforme (GBM) [World Health Organization (WHO) grade IV astrocytoma] patients (Parsons et al., 2008). Later IDH1 and IDH2 mutations...
were reported in acute myeloid leukaemia notably in patients lacking chromosomal abnormalities (Marcuccii et al., 2010). Recently IDH mutations have been reported in many cancers, including chondrosarcomas (Amary et al., 2011), acute lymphoblastic leukaemia (ALL) (Zhang et al., 2012), MDS (Patnaik et al., 2012), AITL (Cairns et al., 2012), cholangiocarcinomas (Borger et al., 2012) and pancreatic cancer (Ghia et al., 2012).

In all the reported cases, IDH mutations were heterozygous in nature and frequently seen at evolutionary conserved arginine residues in the substrate binding site of the enzyme (R132 in IDH1 and R140 and R172 in IDH2) (Losman et al., 2013). As a result of this amino acid substitution, it gains a neomorphic function to produce a oncometabolite 2-Hydroxy glutarate (2-HG) from isocitrate instead of α-ketoglutarate (αKG) (Dang et al., 2009). This elevated level of 2-HG competes with α-KG for binding dioxygenases such as Jumonji family of histone demethylases (Xu et al., 2011) and Tet2 (Figueroa et al., 2010), which are involved in DNA demethylation process. As a result, cells with IDH mutation display hypermethylation as well as cellular differentiation blockage (Figueroa et al., 2010).

In previous studies from various countries, the frequency of IDH mutations in AML patients ranges from 2% to 14% for IDH1 and 1% to 19% for IDH2 (Chotirat et al., 2012; Ahmad et al., 2014). Due to these discrepant frequencies it is necessary to study the mutation status in different regions. In India, to date, there is only one study by Ahmad et al. in 2014 investigated IDH1 and IDH2 mutations in de novo acute myeloid leukaemia patients (Ahmad et al., 2014). They analyzed IDH1 and IDH2 mutations in a cohort of 45 de novo patients exclusively in patients with normal karyotype. To the best of our knowledge, there are no available data regarding IDH1 and IDH2 mutations in cytogenetically unselected adult de novo AML patients in India. In the present study, we aimed to characterize IDH1 and IDH2 mutations in large cohort of 200 newly diagnosed unselected adult AML patients and investigate their correlation with clinical and cytogenetic parameters. Based on the previous published data, we also analyzed the frequency and type of NPM1 mutation, one of the most concurrent mutated gene in IDH mutated cases (Chotirat et al., 2012; Im et al., 2014).

Materials and Methods

Patients

A total of 200 de novo adult AML patients treated at the Regional cancer centre, Trivandrum, India were studied. Informed consent for research purpose was obtained from all the patients and the study approval was obtained from the institutional review board. AML samples were classified according to FAB criteria. The study population consisted of 200 patients, of which 91 were males and 109 were females, with median age 39 years ranging from 18 to 72 years.

Cytogenetic and FISH analysis

Bone marrow aspirate withdrawn at the time of disease diagnosis was used for classical cytogenetic analysis after short-term culture. Harvesting and GTG banding were performed as per the standard procedure (Henegariu et al., 2001). Karyotypes were described according to ISCN 2013 (Shaffer et al., 2013). Twenty metaphases were karyotyped using Cytovision Software (Cytovision, USA). FISH analysis was performed to determine recurring gene fusions (RUNX1-RUNX1T, PML-RARA, and CBFB-MYH11) associated with specific FAB subtypes M2, M3 and M4, respectively using Vysis probes (Abbott Molecular/ Vysis, Des Plains, IL). The slides were hybridized overnight following the Abbott Molecular/Vysis protocol.

IDH1 and IDH2 mutation detection

Genomic DNA was isolated from peripheral blood or bone marrow samples using standard phenol-chloroform method. Exon 4 of IDH1 and IDH2 were amplified by polymerase chain reaction using the primer pair; IDH1F (5′-AGCTCTATATGCCATCAC TGC-3′), IDH1R (5′-AACATGCAAATCACATTATGCCC-3′), and IDH2F (5′-AATTCTAGACCCCCGTCTG-3′), and IDH2R (5′-CTGAGAAGAGGATGGAT-3′) (Chotirat et al., 2012). The PCR performed in a 25 µl reaction containing 50 ng of genomic DNA, 1.5 mM MgCl₂, 0.2 mM dNTPs, 12.5 pmol of each oligonucleotide primers, and 0.5 units of Taq polymerase (Merck, Germany). The PCR condition consisted of an initial denaturation step at 98°C for 30 seconds, followed by 35 cycles at 98°C for 10 Sec, 62°C for 30 Sec, 72°C for 30 Sec and a final step at 72°C for 5 min for IDH1 and initial denaturation step at 98°C for 30 seconds, followed by 35 cycles at 98°C for 10 Sec, 61°C for 30 Sec, 72°C for 30 Sec and a final step at 72°C for 5 min for IDH2. Then the PCR products were analyzed for single-strand mobility patterns and the samples showing altered mobility were sequenced in both sense and antisense directions to confirming the mutations. The sequences were compared to the wild type IDH1 and IDH2 cDNA (GenBank Accession number, NM_005896.2 and NM_002168.2, respectively).

NPM1 mutation detection

For the screening of the NPM1 mutation, we amplified genomic DNA corresponding to exon 12 of NPM1 by PCR using the primers NPM1F (5′-CTAGAGTTAATCTCTCTGGTG-3′) and NPM1R (5′-CCTGGACAACATTTATCAAT-3′) as previously reported (Ahmad et al., 2009). The Briefly PCR reaction was performed in a 25 µl reaction containing 50 ng of genomic DNA, 1.5 mM MgCl₂, 0.2 mM dNTPs, 10 pmol of each oligonucleotide primers, and 0.5 units of Taq polymerase (Merck, Germany). The PCR condition consisted of an initial denaturation step at 95°C for 5 min followed by 35 cycles at 94°C for 30s, 57°C for 1 min, 72°C for 1 min and a final step at 72°C for 10 min. Then the PCR products were analyzed for single-strand mobility patterns and the samples showing altered mobility were sequenced for confirming the mutations. The sequences were compared to the wild type NPM1 cDNA (GenBank Accession number, NM_005896.2 and NM_002168.2, respectively).

Statistical analysis

Data was analyzed using the SPSS software 21. Chi-
Mutation Analysis of IDH1/2 Genes in Unselected De Novo Acute Myeloid Leukaemia Patients in India

DOI:http://dx.doi.org/10.7314/APJCP.2015.16.9.4095

Results

Characterization of IDH1 and IDH2 mutations

In a total of 200 de novo AML patients, 19 (9.5%) patient samples showed aberrant band shifts in PCR-SSCP analysis. Further, it was confirmed as mutation by sequencing analysis. IDH mutations were predominantly found in IDH1 as eleven (5.5%) patients had IDH1 mutations. There were three types of missence IDH1 mutations, including the most reported c.394C>T; p.R132C in nine cases, c.394C>G; p.R132G in one case and c.394C>A; p.R132S in one case (Table 1) (Fig 1.A,B&C). All the mutated cases showed a change in 132 nd arginine to cysteine/glycine/serine. Apart from these, three patients had a coexisting IDH1 mutation and previously reported prognostically relevant synonymous SNP rs11554137 (IDH1105 GGT). Among these, two patients had both c.394C>T and heterozygous IDH1 SNP rs11554137 and one patient had concurrent c.394C>A and homozygous IDH1 SNP rs11554137. Regarding IDH2 mutations, only eight (4%) patients had an IDH2 missence mutation, included c.515G>A; p.R172K in seven cases and c.515_516GG>AA; p.R172K in one case (Table 2) (Fig 1.D & E). Similar to the IDH1 mutations, these cases also showed a change in arginine amino acid. Among this c.515_516GG>AA was a novel mutation that has not yet been reported. No mutated cases harbored mutations both in IDH1 and IDH2 genes, indicating that these mutations are mutually exclusive. All the mutated cases were heterogeneous in nature and retained the wild type allele.

Table 1. The Mutation Patterns and Type of NPM1 Mutations in AML Patients with IDH1 Mutations

| Sl.No. | Age/Sex | FAB | Karyotype | Mutation | Nucleotide change | Aminoacid change | Type of NPM1 mutation |
|-------|---------|-----|-----------|----------|-------------------|------------------|----------------------|
| 1     | 24/F    | M1  | Normal    | c.394C>T | CGT-GTG           | p.R132C          | None                 |
| 2     | 57/F    | M2  | Normal    | c.394C>G | CGT-GGT           | p.R132G          | c.860-863dupTCTG     |
| 3     | 52/F    | M1  | Abnormal  | c.394C>T | CGT-GTG           | p.R132C          | c.860-863dupTCTG     |
| 4     | 40/F    | M1  | Abnormal  | c.394C>G | CGT-GTG           | p.R132C          | c.860-863dupTCTG     |
| 5     | 32/M    | M2  | Normal    | c.394C>T | CGT-GTG           | p.R132C          | None                 |
| 6     | 39/F    | M1  | Normal    | c.394C>T | CGT-GTG           | p.R132C          | None                 |
| 7     | 52/M    | M1  | Normal    | c.394C>T | CGT-GTG           | p.R132C          | None                 |
| 8     | 62/F    | M1  | Normal    | c.394C>T | CGT-GTG           | p.R132C          | None                 |
| 9     | 54/M    | M1  | Normal    | c.394C>A | CGT-AGT           | p.R132S          | None                 |
| 10    | 54/F    | M2  | Normal    | c.394C>T | CGT-GTG           | p.R132C          | None                 |
| 11    | 47/M    | M1  | Normal    | c.394C>T | CGT-GTG           | p.R132C          | None                 |

Table 2. The Mutation Patterns and Type of NPM1 Mutations in AML Patients with IDH2 Mutations

| Sl.No. | Age/Sex | FAB | Karyotype | Mutation | Nucleotide change | Aminoacid change | Type of NPM1 mutation |
|-------|---------|-----|-----------|----------|-------------------|------------------|----------------------|
| 1     | 44/F    | M1  | Normal    | c.515G>A | AGG-AAG           | p.R172K          | c.860-863dupTCTG     |
| 2     | 26/M    | M5  | Abnormal  | c.515G>A | AGG-AAG           | p.R172K          | None                 |
| 3     | 52/F    | M5  | Abnormal  | c.515_516GG>AA | AGG-AAG           | p.R172K          | None                 |
| 4     | 70/M    | M5  | Normal    | c.515G>A | AGG-AAG           | p.R172K          | None                 |
| 5     | 55/M    | M5  | Normal    | c.515G>A | AGG-AAG           | p.R172K          | None                 |
| 6     | 63/F    | M2  | Normal    | c.515G>A | AGG-AAG           | p.R172K          | None                 |
| 7     | 56/M    | M5  | Normal    | c.515G>A | AGG-AAG           | p.R172K          | None                 |
| 8     | 34/F    | M1  | Normal    | c.515G>A | AGG-AAG           | p.R172K          | None                 |

Correlation of IDH1 and IDH2 mutations with clinical parameters and morphological subtypes

IDH1 mutations were more predominant in female patients than in male patients (3M/8F). However, the difference was not significant. The median age was 52 in IDH1 mutated cases compared to 38 in unmutated cases. IDH1 mutated subjects had significantly higher platelet count and Hb level compared with the unmutated cases (P<0.001 and P<0.05, respectively). There was no significant statistical difference in WBC counts and bone marrow blasts between IDH1 mutated and wildtype cases (Table 3). Unlike IDH1 cases, IDH2 mutated subjects had
Correlation of IDH1 and IDH2 mutations with chromosomal pattern and NPM1 mutation

Karyotypic analysis was available in 187 out of 200 samples. Among these, 110 patients had a normal and 77 had an abnormal karyotypic pattern. In eleven IDH1 mutated cases there were a higher frequency of patients with recurrent chromosomal abnormalities (eg. +8). Noticeably, there were no IDH mutations in cases with recurrent chromosomal abnormalities (eg. t(15;17), t(8;21) and inv(16)). Analysis of frequency and type NPM1 mutation in the IDH mutated cases revealed an interesting result. Among eleven IDH1 mutated patients, we found 8 cases with NPM1 mutation with a statistical significance p=0.001. Unlike IDH1 mutated cases, in eight IDH2 mutated patients only one case showed NPM1 mutation. Strikingly, all the NPM1 mutations were type A mutation (c.860_863dupTCTG) (Figure 1F) that causes a change in the reading frame of the C-terminal portion of nucleosomin.

Discussion

Although IDH mutations were extensively studied in AML around the world, only one study by Ahmad et al. in a 45 normal karyotype AML (NK-AML) patients had published from India (Ahmad et al., 2014). In the present study, we have analyzed IDH1/2 mutations in a large cohort of 200 newly diagnosed unsellected adult AML patients and investigated their correlation with clinical, cytogenetic parameters along with NPM1 mutation. In this study, IDH mutations were observed in 19 patients, which include eleven patients with IDH1 mutations and eight patients with IDH2 mutations.

Among IDH mutations, IDH1 mutations are one of the predominant mutations in glioma and the second most common in acute myeloid leukaemia. The frequency of
IDH1 mutations in AML patients from various countries ranges from 2% to 14% (Chotirat et al., 2012; Ahmad et al., 2014). In the present study, we got 5.5% IDH1 mutation which is comparable with most of the previous reports from other countries (Abbas et al., 2010; Figueroa et al., 2010; Patel et al., 2011). Considering the IDH1 mutation frequency in Asian countries, our mutation frequency is similar to Taiwan (5.5%), almost similar to Chinese (3.6%, 5.9% and 6.7%) and somewhat lesser to Thailand (8.7%) and Japanese (8.6%) reports (Chou et al., 2010; Zou et al., 2010; Lin et al., 2011; Zhang et al., 2011; Chotirat et al., 2012; Yamaguchi et al., 2014). This discrepancy in the incidence rate may be due to ethnic variation (Zou et al., 2010). The majority of the reported mutations in the IDH1 gene bring about an amino acid substitution at 132nd arginine residue in the substrate binding site of the enzyme (Paschka et al., 2010). Among the three IDH1 missense mutations (c.394C>T, p.R132C; c.394C>A, p.R132S and c.394C>G, p.R132G), c.394C>T was the predominant mutation (n=9, 82%), followed by c.394C>A (n=1, 9%) and c.394C>G (n=1, 9%). The predominance of c.394C>T, p.R132C mutation in our study is similar to most of the Asian studies (Chou et al., 2010; Kou et al., 2010; Lin et al., 2011; Zhang et al., 2011; Chotirat et al., 2012; Yamaguchi et al., 2014). Among these c.394C>T mutation, the most reported IDH2 mutation in AML was the predominant mutation (n=7, 87.5%), followed by a previously unreported complex-compound substitution c.515_516 GG>AA (n=1, 12.5%). Alike c.515G>A mutation, the novel c.515_516GG>AA mutation replaces 172nd arginine to lysine in the active site of the enzyme. Owing to this similar change we hypothesized that the novel c.515G>A mutation replaces 172nd arginine to lysine in the active site of the enzyme.

Table 4. Clinical Details of AML with IDH2 Mutations

|                          | Total (%) | IDH1* | IDH1 | p-value |
|--------------------------|-----------|-------|------|---------|
| All patients             | 200       | 4%(8/200) | 96%(192/200) |         |
| Male/Female Ratio        | 91/109    | 4/4   | 87/105 | NS      |
| Median age, Yrs(range)   | 39(18-72) | 53.5(26-70) | 38.5(18-72) | <0.05   |
| Median WBCX10^9/L (range)| 16.7(0.7-404) | 2.2(0.7-116) | 17.7(0.8-404) | <0.05   |
| Median plateletX10^9/L   | 38.5(0.7-367) | 63(5-208) | 37(0.7-367) | NS      |
| Median Hb, gm%(range)    | 8.1(1.8-17) | 8.1(7.3-10.3) | 8.1(1.8-17) | NS      |
| Median BM Blast, %(range)| 72(6-99)  | 76(27-96) | 71.5(6-99) | NS      |
| FAB subtypes             |           |       |      |         |
| AML-M0                   | 0.5%(1/200) | 0     | 100%(1/1) | -       |
| AML-M1                   | 22.5%(45/200) | 4.5%(2/45) | 95.5%(43/45) | NS      |
| AML-M2                   | 22.5%(45/200) | 2.2%(1/45) | 97.8%(44/45) | NS      |
| AML-M3                   | 13.5%(27/200) | 0     | 100%(27/27) | -       |
| AML-M4                   | 19%(38/200)  | 0     | 100%(38/38) | -       |
| AML-M5                   | 21%(42/200)  | 11.9%(5/42) | 88.1%(37/42) | NS      |
| AML-M6                   | 1%(2/200)  | 0     | 100%(2/2) | -       |
| AML-M7                   | 0         | 0     | 0     | -       |
| Cytogenetics             |           |       |      |         |
| Total                   | 200       |       |      |         |
| Total cytogenetics     | 187       |       |      |         |
| Normal karyotype        | 55%(110/200) | 5.5%(6/110) | 94.5%(104/110) | NS      |
| Abnormal                |           |       |      |         |
| t(8;21)                 | 13.5%(27/200) | 0     | 100%(27/27) | -       |
| t(15;17)                | 11.5%(23/200) | 0     | 100%(23/23) | -       |
| inv(16)                 | 4%(8/200)  | 0     | 100%(8/8) | -       |
| Trisomy 8               | 2%(4/200)  | 25%(1/4) | 75%(3/4) | NS      |
| Other trisomies         | 2.5%(5/200) | 20%(1/5) | 80%(4/5) | NS      |
| Monosomies or deletions | 2%(4/200)  | 0     | 100%(4/4) | -       |
| Complex                 | 3%(6/200)  | 0     | 100%(6/6) | -       |
| Unknown                 | 6.5%(13/200) | 0     | 100%(13/13) | -       |
| NPM1                    | 21.5%(43/200) | 12.5%(1/8) | 21.9%(42/192) | NS      |

*NS: not significant

The frequency of IDH2 mutations in AML patients in earlier studies ranges from 1% to 19% (Chotirat et al., 2012; Ahmad et al., 2014). In the present study, we got 4% IDH2 mutation. But the incidence rate of IDH2 mutations is significantly lower than all Asian reports [Thailand (10.4%) and Japan (8.2%)] and majority of the western reports (Paschka et al., 2010; Figueroa et al., 2010; Ward et al., 2010; Abbas et al., 2010; Chotirat et al., 2012; Yamaguchi et al., 2014). Among the reported IDH2 mutations in acute myeloid leukaemia, R140Q mutations is the predominant mutations followed by R172K; bring about a change in arginine residue of the enzyme (Abbas et al., 2010; Chou et al., 2010; Ward et al., 2010). Contradictory to the most of the asian reports where the most predominant mutations are R140Q, all our identified mutations were R172K (c.515G>A, p.R172K; c.515_516GG>AA, p.R172K) (Chotirat et al., 2012; Yamaguchi et al., 2014). Among these c.515G>A, the most reported IDH2 mutation in AML was the predominant mutation (n=7, 87.5%), followed by a previously unreported complex-compound substitution c.515_516 GG>AA (n=1, 12.5%). Alike c.515G>A mutation, the novel c.515_516GG>AA mutation replaces 172nd arginine to lysine in the active site of the enzyme. Owing to this similar change we hypothesized that the novel c.515_516GG>AA might have a similar effect as c.515G>A in AML pathogenesis.

Out of nineteen mutated IDH subjects, fifteen (15/19, 79%) of them showed a normal karyotype pattern, which
1. Background:

Mutations in the genes encoding IDH1 and IDH2 both are recurrent events in adult Indian AML patients. Even though there was a preponderance of IDH mutations in NK-AML, cytogenetically abnormal patients also harboured IDH mutations. IDH1 mutations display significant higher platelet counts and NPM1 mutations. IDH2 mutated patients showed frequent NPM1 mutations and lower WBC count. Noticeably all the NPM1 mutations in the IDH mutated cases were type A mutation. Identified IDH2 novel c.515_516GG>AA mutation replaces 172 His, Leu or Ser. Mutations in IDH2 are more frequently a change in the Arg-132 to other amino acids like Cys, His, Leu or Ser. Mutations in IDH2 are more frequently at R140 and less frequently at R172 (Marcuccii et al., 2010). The mutations that occur at a single amino acid residue of the IDH1 and IDH2 active site not only reduce the enzyme’s ability to catalyze conversion of isocitrate to α-ketoglutarate but also acquire a new ability to catalyze the NADPH-dependent reduction of α-ketoglutarate to R(-)-2-hydrox-yglutarate (2HG) (Dang et al., 2009; Ward et al., 2010). The recent studies also suggest that the excess 2HG which accumulates in vivo contributes to the formation and malignant progression. Furthermore, the majority of the IDH mutations in AML is associated with mutations in NPM1 gene, one of the first hit mutated gene in AML (Im et al., 2014). So it was speculated that IDH mutations are likely to be associated with disease progression rather than disease initiation (Chotirat et al., 2012). Even though patients with mutated IDH1 have a better prognosis in glioma, the prognostic significance of IDH mutations in AML is still unclear (Van den Bent et al., 2010; Döhner et al., 2011; Shih et al., 2012). However, recent studies show that IDH1 mutations are associated with favourable prognosis in AML patients with normal karyotype and an NPM1 mutation (Patel et al., 2012; Yamaguchi et al., 2014).

To summarize, we identified 9.5% IDH mutations, predominantly IDH1 mutations in 200 unselected de novo adult Indian AML patients. Even though there was a preponderance of IDH mutations in NK-AML, cytogenetically abnormal patients also harboured IDH mutations. IDH1 mutations display significant higher platelet count and NPM1 mutations. IDH2 mutated patients showed frequent NPM1 mutations and lower WBC count. Noticeably all the NPM1 mutations in the IDH mutated cases were type A mutation. Identified IDH2 novel c.515_516GG>AA mutation replaces 172nd arginine to lysine in the active site of the enzyme. Further studies with survival analysis of patients are needed for the prognostic stratification of IDH mutations in AML.

2. References:

Abbas S, Lughart S, Kavelaars FG, et al (2010). Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukaemia: prevalence and prognostic value. Blood, 116, 2122-6.

Ahmad F, Mohota R, Sanap S, et al (2014). Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukaemia patients. Asian Pac J Cancer Prev, 15, 1247-53.

Ahmad F, Mandava S, Das BR (2009). Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population. Hematol Oncol, 27, 90-7.

Amary MF, Bacci K, Maggiani F, et al (2011). IDH1 and IDH2 mutations are frequent events in central chordrosarcoma and central and periostral chordomas but not in other mesenchymal tumours. J Pathol, 224, 334-43.

Borger DR, Tanabe KK, Fan KC, et al (2012). Frequent mutation of isocitrate dehydrogenase (IDH1 and IDH2 in cholangiocarcinoma identified through broad-based tumor
genotyping. *Oncologist*, 17, 72-9.

c) Cairns RA, Iqbal J, Lemmonn F, et al (2012). IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. *Blood*, 119, 1901-3.

Chottirat S, Thongnoppakhun W, Promsuwicha O, et al (2012). Molecular alterations of Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. *J Hematol Oncol*, 5, 1-10.

Chou WC, Hou HA, Chen CY, et al (2010). Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. *Blood*, 115, 2749-54.

Conway O’Brien E, Prideaux S, Chevassut T (2014). The epigenetic landscape of acute myeloid leukemia. *Adv Hematol*, 2014, 1-15.

Dang L, Jin S, Su SM (2010). IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med, 16, 387-397.

Dang L, White DW, Gross S, et al (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature*, 462, 739-44.

Döhner H, Gaidzik VI (2011). Impact of genetic features on treatment decisions in AML. *Hematology Am Soc Hematol Educ Program*, 2011, 36-42.

Figueroa ME, Abdel-Wahab O, Lu C, et al (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell*, 18, 553-67.

Ghiari AF, Cairns RA, Thoms J, et al (2012). IDH mutation status in prostate cancer. *Oncogene*, 31, 3826.

Henegariu O, Heerema NA, Lowe Wright L, et al (2001). The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell*, 8, 92-7.

Horn PS, Patel J, Wise DR, et al (2010). The role of mutations in epigenetic regulators in myeloid malignancies. *Nat Rev Cancer*, 12, 599-612.

Van den Bent MJ, Dubink HJ, Marie Y, et al (2010). IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendrogial tumors: a report of the European organization for research and treatment of cancer brain tumor group. *Clin Cancer Res*, 16, 1597-604.

Im AP, Sehgal AR, Carroll MP, et al (2014). DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. *Leukemia*, 28, 1774-83.

Ley TJ, Miller C, Ding L, et al (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med*, 368, 2059-74.

Lin J, Qian J, Yao DM, et al (2011). Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis. *Clin Biochem*, 44, 779-83.

Losman JA, Kaelin WG Jr (2013). What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. *Genes Dev*, 27, 836-52.

Marucci G, Maharry K, Wu YZ, et al (2010). IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cyogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. *J Clin Oncol*, 28, 2348-55.

Mardis ER, Ding L, Dooling DJ, et al (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. *N Engl J Med*, 361, 1058-66.

Parsons DW, Jones S, Zhang X, et al (2008). An integrated genomic analysis of human glioblastoma multiforme. *Science*, 321, 1807-12.

Paschka P, Schlenk RF, Gaidzik VI, et al (2010). IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cyogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. *J Clin Oncol*, 28, 3636-43.

Patel KP, Ravandi F, Ma D, et al (2011). Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. *Am J Clin Pathol*, 135, 35-45.

Patel JP, Gönen M, Figueroa ME, et al (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N Engl J Med*, 366, 1079-89.

Patnaik MM, Hanson CA, Hedrick JL, et al (2012). Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. *Leukemia*, 26, 101-5.

Shaffer LG, McGowan-Jordan J, Schmid M (eds). ISCN 2013: An International System for Human Cytogenetic Nomenclature (2013). Basel, Karger, 2013.

Shih AH, Abdel-Wahab O, Patel JP et al (2012). The role of mutations in epigenetic regulators in myeloid malignancies. *Nat Rev Cancer*, 12, 599-612.

Van den Bent MJ, Dubink HJ, Marie Y, et al (2010). IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendrogial tumors: a report of the European organization for research and treatment of cancer brain tumor group. *Clin Cancer Res*, 16, 1597-604.

Wagner K, Damm F, Göhring G, et al (2010). Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cyogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. *J Clin Oncol*, 28, 2356-64.

Ward PS, Patel J, Wise DR, et al (2010). The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell*, 17, 225-34.

Xu W, Yang H, Liu Y, et al (2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. *Cancer Cell*, 19, 17-30.

Xu X, Zhao J, Xue Z, et al (2004). Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. *J Biol Chem*, 279, 33946-57.

Yamaguchi S, Iwanaga E, Tokunaga K, et al (2014). IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation. *Eur J Haematol*, 92, 471-7.

Zhang Y, Wei H, Tang K, et al (2012). Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia. *Genet Test Mol Biomarkers*, 16, 991-5.

Zhang Y, Wei H, Wang M, et al (2011). Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients. *Leukemia*, 35, 1301-6.

Zou Y, Zeng Y, Zhang DF, et al (2010). IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. *Biochem Biophys Res Commun*, 402, 378-83.